Search results with tag "Erbitux"
HIGHLIGHTS OF PRESCRIBING INFORMATION forERBITUX. …
pi.lilly.com• ERBITUX can cause serious and fatal infusion reactions. (5.1, 6)Immediately interrupt and permanently discontinue ERBITUX for serious infusionreactions.(2.5) • Cardiopulmonary arrest or sudden death occurred in patients with squamous cell carcinoma of the head and
HIGHLIGHTS OF PRESCRIBING INFORMATION forERBITUX. …
pi.lilly.cominfectious sequelae (e.g.,acneiform rash, mucocutaneous disease) [see Warnings and Precautions (5.4)] 1stoccurrence; Grade 3 or 4 Delay infusion 1 to 2 weeks; if condition improves,continue at 250mg/m2. If no improvement, discontinue ERBITUX. 2nd occurrence; Grade 3 or 4 Delay infusion 1 to 2 weeks;if condition improves,continue at 200mg/m2.
Biotecnología y Medicamentos Biológicos - medigraphic.com
www.medigraphic.com• Erbitux ® ~cetuximab anticuerpo quimérico anti factor de crecimiento epidérmico • Vectibix ® panitumumab anticuerpo humanizado anti factor de crecimiento epidérmico. • Herceptin ® trastuzumab anticuerpo humanizado anti-HER2 Inmunomodulación selectiva para tratar específicamente diversas enfermedades autoinmunes:
Development of therapeutic antibodies for the treatment of ...
jbiomedsci.biomedcentral.comCetuximab Erbitux Bristol-Myers Squibb/Merck & Co. Inc./Eli Lilly/ImClone Systems Inc. EGFR Chimeric IgG1 Hybridoma Colorectal cancer 2004 Bevacizumab Avastin Roche, F. Hoffmann-La Roche, Ltd./ Genentech Inc. VEGF-A Humanized IgG1 Hybridoma Colorectal cancer 2004 Natalizumab Tysabri Biogen Inc./Elan Pharmaceuticals International, Ltd.
Procedures, programs and drugs that require ... - Aetna
www.aetna.comErbitux (cetuximab) Erythropoiesis-stimulating agents: Aranesp (darbepoetin alfa) Epogen (epoetin alfa) Mircera (epoetin beta) Procrit (epoetin alfa) Retacrit (recombinant human erythropoietin) Evkeeza (evinacumab-dgnb) — precertification for the drug and site of care required effective 5/7/2021 . Evrysdi (risdiplam) Feraheme (ferumoxytol)
FoundationOne CDx Intended Use Table 1 - Foundation …
info.foundationmedicine.comErbitux® (cetuximab) KRAS wild-type (absence of mutations in exons 2, 3, and 4) and NRAS wild type (absence of mutations in exons 2, 3, and 4) Vectibix® (panitumumab) Ovarian cancer BRCA1/2 alterations Lynparza® (olaparib) or Rubraca® (rucaparib) Cholangiocarcinoma FGFR2 fusions and select rearrangements Pemazyre® (pemigatinib) or
508C Provider-Administered Specialty Pharmacy Products
www.bcbst.comErbitux . Commercial Members Only: For therapies noted below with a “2,” and highlighted in . green, please fax authorization requests to Commercial Utilization Management at . 1-866-558-0789. or call . 1- 800-924-7141. Follow prompts to Prior Authorization then select option 9 .
University of New Mexico http://danielsethics.mgt.unm.edu ...
danielsethics.mgt.unm.eduLater investigations revealed that after learning the FDA would refuse to review Erbitux, Sam Waksal, the CEO of ImClone and a close friend of Stewart, instructed his broker Peter Bacanovic— who was also Stewart’s broker—to transfer $4.9 million in stock to the account of his daughter Aliza Waksal.